Stockreport

Flexion Therapeutics Announces Positive Preclinical Data Supporting Development of FX301, a Locally Administered Nav1.7 Inhibitor Product Candidate for Post-Operative Pain

Flexion Therapeutics, Inc.  (FLXN) 
Last flexion therapeutics, inc. earnings: 11/7 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.flexiontherapeutics.com
PDF New animal data show FX301 provided sustained, post-operative analgesic effect with no impairment in motor function compared to liposomal bupivacaine and placebo High lo [Read more]